Document is current
Any future updates will be listed below
-
Authors
Tselikas, Lambros
Susini, Sandrine https://orcid.org/0000-0002-2561-6528
Texier, Matthieu
Yurchenko, Andrey https://orcid.org/0000-0002-2239-6902
Routier, Emilie
Amini-Adle, Mona
Tihic, Edi
Mouraud, Séverine https://orcid.org/0000-0003-3264-6298
Danlos, François-Xavier
Ammari, Samy
Raoult, Thibault https://orcid.org/0000-0003-4574-3978
Roy, Séverine
Bredel, Delphine
Farhane, Siham
Cassard, Lydie
Molinaro, Irma
Eggermont, Alexander
Soria, Jean-Charles
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
Massard, Christophe
Paci, Angelo https://orcid.org/0000-0002-4849-0825
de Baere, Thierry https://orcid.org/0000-0002-4556-7663
Scoazec, Jean-Yves https://orcid.org/0000-0003-1604-6823
Chaput, Nathalie https://orcid.org/0000-0003-2506-7853
Nikolaev, Sergey https://orcid.org/0000-0001-8587-2307
Meyer, Nicolas
Lebbé, Céleste
Dalle, Stéphane
Robert, Caroline https://orcid.org/0000-0002-9493-0238
Marabelle, Aurélien https://orcid.org/0000-0002-5816-3019
- License Information
-
More Information
Article History
Received: 17 August 2025
Accepted: 27 February 2026
First Online: 29 April 2026
Competing interests
: L.T., F.-X.D., D.B., S.S., S.M., C.R. and A.M. are listed as authors on patent application EP4430403A1 ( Products and Uses Thereof for Predicting the Sensitivity of a Subject to Cancer Immunotherapy and for Selecting Optimized Therapy ) and S.S., L.T. and A.M. are listed as authors on patent application WO2024251978A1 ( Drug Conjugate Targeting CTLA4, Products Comprising the Same and Therapeutic Uses Thereof ). The other authors declare no competing interests.
